{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:59:29Z","timestamp":1775321969675,"version":"3.50.1"},"reference-count":50,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.5551\/jat.63019","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T22:07:43Z","timestamp":1630274863000},"page":"1188-1200","source":"Crossref","is-referenced-by-count":9,"title":["Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study"],"prefix":"10.5551","volume":"29","author":[{"given":"Ryo","family":"Naito","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisaku","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[{"name":"The National Center for Geriatrics and Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bujo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory and Experimental Research Medicine, Toho University, Sakura Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Koga","sequence":"additional","affiliation":[{"name":"Shin Koga Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Director of Diabetes and Lifestyle-related Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association (JATA)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Department of Community Medicine, Osaka University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Luis Masana, Reiner Z, Taskinen M-R, Tokg\u00f6zoglu L, Tybj\u00e6rg-Hansen A, European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31: 2844-2853","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Emerging Risk Factors Collaboration; Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423","DOI":"10.1001\/jama.2009.1063"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kamstrup PR, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation, 2008; 117: 176-184","DOI":"10.1161\/CIRCULATIONAHA.107.715698"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) McGowan MP, Dehkordi SHH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc, 2019; 8: e013225","DOI":"10.1161\/JAHA.119.013225"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T, Research Committee on Primary Hyperlipidemia of the Ministry of Health, Labour, and Welfare of Japan. Clinical features of familial hypercholesterolemia in Japan in a database from 1996\u22121998 by the Research Committee of the Ministry of Health, Labour and Welfare of Japan. J Atheroscler Thromb, 2004; 11: 146-151","DOI":"10.5551\/jat.11.146"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol, 2016; 67: 2578-2589","DOI":"10.1016\/j.jacc.2016.03.520"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tada H, Kawashiri M, Yoshida T, Teramoto R, Nohara A, Konno T, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations. Circ J, 2016; 80: 512-518","DOI":"10.1253\/circj.CJ-15-0999"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamashita S, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Daida H, Koga N, and Oikawa S, on Behalf of the FAME Study Group. Effectiveness and Safety of Lipid-lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb, 2021; Advanced publication. doi: http:\/\/doi.org\/10.5551\/jat.62764","DOI":"10.5551\/jat.62764"},{"key":"9","unstructured":"9) Harada-Shiba M. Evaluation of clinical management guidelines for familial hypercholesterolemia. Research Committee of Primary Hyperlipidemia supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Health, Labor and Welfare. Study Report in 2008, 2009; 50-55 (in Japanese)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol, 2018; 71: 177-192","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol, 2017; 69: 692-711","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol, 1992; 136: 441-449","DOI":"10.1093\/oxfordjournals.aje.a116517"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta, 2001; 312: 87-95","DOI":"10.1016\/S0009-8981(01)00591-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Aono H, Ito M, Ozawa H, Waki T, Magari Y, Bello MC, Rodoriguez AG. Lipoprotein(a) concentrations in healthy subjects in the Dominican Republic. Comparison with Japanese. Jpn Heart J, 1999; 40: 65-70","DOI":"10.1536\/jhj.40.65"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S, Mackness M, Lockley P, Miller JP. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb, 1991; 11: 940-946","DOI":"10.1161\/01.ATV.11.4.940"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Friedlander Y, Leitersdorf E. Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genet Epidemiol, 1995; 12: 129-143","DOI":"10.1002\/gepi.1370120203"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Soutar AK, McCarthy SN, Seed M, Knight BL. Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro6643leu mutation in the LDL receptor gene. J Clin Invest, 1991; 88: 483-492","DOI":"10.1172\/JCI115329"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Defesche JC, van de Ree MA, Kastelein JJ, van Diermen DE, Janssens NW, van Doormaal JJ, Hayden MR. Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada. Clin Genet, 1992; 42: 273-280","DOI":"10.1111\/j.1399-0004.1992.tb03255.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Patel JV, Vyas A, Cruickshank JK, Prabhakaran D, Hughes E, Reddy KS, Mackness MI, Bhatnagar D, Durrington PN. Impact of migration on coronary heart disease risk factors: Comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis, 2006; 185:297-306","DOI":"10.1016\/j.atherosclerosis.2005.06.005"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Agoston-Coldea L, Mocan T, Gatfoss\u00e9 M, Dumitrascu DL. The correlation of apolipoprotein B, apolipoprotein B\/apolipoprotein A-I ratio and lipoprotein(a) with myocardial infarction. Cent Eur J Med, 2008; 3: 422-429","DOI":"10.2478\/s11536-008-0057-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kamboh M, Rewers M, Aston CE, Hamman RF. Plasma apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) concentrations in normoglycemic Hispanics and non-Hispanic whites from the San Luis Valley, Colorado. Am J Epidemiol, 1997; 146: 1011-1018","DOI":"10.1093\/oxfordjournals.aje.a009229"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Albers JJ, Marcovina SM, Imperatore G, Snively BM, Stafford J, Fujimoto WY, Mayer-Davis EJ, Petitti DB, Pihoker C, Dolan L, Dabelea DM. Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab, 2008; 93: 735-742","DOI":"10.1210\/jc.2007-2176"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Croyal M, Blanchard V, Ouguerram K, Ch\u00e9tiveaux M, Cabioch L, Moyon T, Billon-Crossouard S, Aguesse A, Bernardeau K, May CL, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nob\u00e9court-Dupuy E. VLDL (very-low-density lipoprotein)-apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly. Arterioscler Thromb Vasc Biol, 2020; 40: 819-829","DOI":"10.1161\/ATVBAHA.119.313877"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kostner GM, Wo X, Frank S, Kostner K, Zimmermann R, Steyrer E. Metabolism of Lp(a): assembly and excretion. Clin Genet, 2008; 52: 347-354","DOI":"10.1111\/j.1399-0004.1997.tb04352.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kostner KM, Kostner GM. Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med, 2004; 4: 211-214","DOI":"10.1055\/s-2004-835380"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). Med Sci Sports Exerc, 1997; 29: 1429-1436","DOI":"10.1097\/00005768-199711000-00007"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: where are we now? Curr Opin Cardiol, 2009; 24: 351-357","DOI":"10.1097\/HCO.0b013e32832ac21a"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Takami S, Kubo M, Yamashita S, Kameda-Takemura K, Kawasaki T, Kanbayashi J, Nakamura Y, Yokoi Y, Ohnishi K, Matsuzawa Y. High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans. Atherosclerosis, 1995; 112: 253-260","DOI":"10.1016\/0021-9150(94)05424-H"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation, 1998; 97: 721-728","DOI":"10.1161\/01.CIR.97.8.721"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol, 2012; 60: 716-721","DOI":"10.1016\/j.jacc.2012.04.038"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Watanabe J, Hamasaki M, Kotani K. Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review. Arch Med Sci Atheroscler Dis, 2020; 5: e148-e152","DOI":"10.5114\/amsad.2020.97105"},{"key":"34","unstructured":"34) Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease; a systematic review and meta analysis of prospective studies. Clin Lab, 2011; 57: 143-156"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ariyo AA, Thach C, Tracy R. Lp(a) Lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med, 2003; 349: 2108-2115","DOI":"10.1056\/NEJMoa001066"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation, 1997; 96: 1390-1397","DOI":"10.1161\/01.CIR.96.5.1390"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, Steinhagen-Thiessen E, Endres M, Ebinger M. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis, 2015; 242: 496-503","DOI":"10.1016\/j.atherosclerosis.2015.08.021"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kotani K. Lipoprotein(a) in the advent of a PCSK9 world. Ann Clin Biochem, 2020; 57: 102","DOI":"10.1177\/0004563219884965"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJP, Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the Treating to New Targets Randomized Controlled Trial by lipid and non-lipid biomarkers. PLoS ONE, 2014; 9: e114519","DOI":"10.1371\/journal.pone.0114519"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 2014; 129: 635-642","DOI":"10.1161\/CIRCULATIONAHA.113.004406"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes. J Am Coll Cardiol, 2009; 53: 2186-2196","DOI":"10.1016\/j.jacc.2009.02.041"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol, 2012; 154: 183-186","DOI":"10.1016\/j.ijcard.2011.09.060"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res, 2012; 53: 2405-2412","DOI":"10.1194\/jlr.M029769"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol, 2008; 101: S20-S26","DOI":"10.1016\/j.amjcard.2008.02.029"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267","DOI":"10.1056\/NEJMoa1107579"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014; 371: 203-212","DOI":"10.1056\/NEJMoa1300955"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL, AIM-HIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH Trial. N Engl J Med, 2014; 371: 288-290","DOI":"10.1056\/NEJMc1311039"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs, 2018; 78: 453-462","DOI":"10.1007\/s40265-018-0870-1"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K, Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb, 2018; 25: 751-770","DOI":"10.5551\/jat.CR003"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Scharnagla H, Stojakovica T, Dieplingerb B, Dieplingerc H, Erhartc G, Kostnerd GM, Herrmanna M, M\u00e4rza W, Grammerga T. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis, 2019; 289: 206-213","DOI":"10.1016\/j.atherosclerosis.2019.08.015"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/8\/29_63019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:30:45Z","timestamp":1715232645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/8\/29_63019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63019","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"63019"}}